You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

185 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant, Adjuvant
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Adjuvant, Curative
May 2025
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone
Intent: Adjuvant, Neoadjuvant, Palliative
Sep 2019
Regimen
Intent: Neoadjuvant, Adjuvant
Jun 2020
Regimen
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Neoadjuvant, Adjuvant, Curative, Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Dec 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant
Aug 2021
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Intent: Adjuvant, Curative, Palliative
Dec 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Aug 2021

Pages